Lactate Clearance According to the Presence of Hepatic Dysfunction
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare lactate clearance in patients with severe sepsis and septic shock according to the presence of hepatic dysfunction.
| Condition |
|---|
|
Sepsis Liver Failure |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Lactate Clearance and Mortality in Patients With Severe Sepsis and Septic Shock: Comparison by Hepatic Dysfunction |
- Lactate clearance [ Time Frame: at 6-hour from the time of enrollment ] [ Designated as safety issue: No ][(initial lactate − delayed lactate)/ initial lactate] *100%
- In-hospital mortality [ Time Frame: within the first 28-day after emergency department arrival ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Interleukin-1, Interleukin-6, Interleukin-10, TNF-alfa
| Estimated Enrollment: | 245 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | June 2014 |
| Estimated Primary Completion Date: | June 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
No hepatic dysfunction
No hepatic dysfunction, total plasma bilirubin ≤ 2.0 mg/dl
|
|
Hepatic dysfunction
Hepatic dysfunction, total plasma bilirubin > 2.0 mg/dl
|
Detailed Description:
Lactate clearance is well known to be associated with mortality in patients with severe sepsis and septic shock. To normalize lactate levels is one of important goals of early resuscitation of sepsis patients.
Lactate clearance can be changed by various factors including patient characteristics, severity of shock, and treatment. In particular, hepatic dysfunction might impair the clearance of lactate because liver is a principal organ for lactate metabolism. However, an association between lactate clearance and hepatic failure has not been evaluated during initial resuscitation of patients with severe sepsis and septic shock. The primary goal of this study is to compare lactate clearance in patients with severe sepsis and septic shock according to the presence of hepatic dysfunction. The secondary goal is to evaluate if lactate clearance is associated with mortality even in patients with hepatic dysfunction.
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients presenting to the emergency department and meeting criteria for severe sepsis or septic shock at Samsung Medical Center (a 1,960 bed, university-affiliated, tertiary referral hospital in Seoul, South Korea)
Inclusion Criteria:
- Patients who presented with septic shock or severe sepsis within 6 hours after emergency department arrival
Exclusion Criteria:
- Terminal malignancy or illness with a expected survival < 4 months
- Patients who previously signed "Do Not Resuscitate" or "Do Not Intubate" orders
- Patients who do not undergo the early goal-directed therapy
Contacts and Locations| Contact: Ik Joon Jo, PhD | +82-2-3410-2053 | drjij@skku.edu |
| Korea, Republic of | |
| Samsung Medical Center, Sungkyunkwan University School of Medicine | Recruiting |
| Seoul, Korea, Republic of, 135-710 | |
| Principal Investigator: | Ik Joon Jo, PhD | Samsung Medical Center |
More Information
Publications:
| Responsible Party: | Jo, Ik Joon, Associate Professor, Samsung Medical Center |
| ClinicalTrials.gov Identifier: | NCT01709565 History of Changes |
| Other Study ID Numbers: | SamsungMC |
| Study First Received: | September 17, 2012 |
| Last Updated: | October 16, 2012 |
| Health Authority: | South Korea: Institutional Review Board |
Keywords provided by Samsung Medical Center:
|
Sepsis Lactic acid Shock Resuscitation |
Additional relevant MeSH terms:
|
Sepsis Toxemia Liver Failure Liver Diseases Infection |
Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes Hepatic Insufficiency Digestive System Diseases |
ClinicalTrials.gov processed this record on June 17, 2013